RxDoctor Payments Data

Mark Rea, MD

Interventional Cardiology · Akron, OHNPI 1992849673

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,527 of the $8,571 with a category attached, or 87.8%. 22 manufacturers reported payments, led by Inari Medical, Inc. at 33.8% of the total.

$8,571in general payments, 2019–2025

Across 197 payments — averaging $43.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$3K
  • Abiomed$2K
  • Abbott$722
  • Medtronic$652
  • Stryker$601
  • Boston Scientific$322
  • plus $1K from 16 others
$70,239in research payments, 2019–2025

Across 73 payments — averaging $962.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inari Medical, Inc.$70K

What the payments were for

  • Travel & lodging$86110%
  • Food & beverage$7,52788%
  • Education$1832%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,571 in reported general payments places this provider in the 60th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$81,782
Medicare patients
386
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$56,175
EntrestoSacubitril/Valsartan28$39,867
FarxigaDapagliflozin Propanediol23$35,661
BrilintaTicagrelor11$12,418
Rosuvastatin Calcium175$1,601
Atorvastatin Calcium113$1,541
Metoprolol Succinate123$1,414
Isosorbide Mononitrate ErIsosorbide Mononitrate37$691
Pantoprazole Sodium57$596
Metoprolol Tartrate81$475
ClopidogrelClopidogrel Bisulfate68$472
Carvedilol46$455
Losartan Potassium78$400
Nitroglycerin41$350
Amlodipine Besylate64$334

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →